首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
首頁 > 市場調查報告書 > 製藥 > 目標治療之診斷與治療整合:第 II 部 - 計算投資報酬率的重要性
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

目標治療之診斷與治療整合:第 II 部 - 計算投資報酬率的重要性

Integrating Diagnostics and Therapeutics for Targeted Therapies, Part II: The Importance of Calculating the Return on Investment

出版商 Decision Resources, Inc.
出版日期 2005年12月 商品編碼 38485
內容資訊 英文 Pages: 10
價格
本報告書已不再販售

本報告已在2011年07月19日停止出版。

簡介

診斷與治療之併用受到廣泛認可,製藥企業有必要界定行銷這些併用例子的最佳典範。

專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. (總公司:麻薩諸塞州),針對目標治療之診斷與治療整合進行調查分析,經系統整理後出版報告書  "Integrating Diagnostics and Therapeutics for Targeted Therapies, Part II: The Importance of Calculating the Return on Investment" 。

本報告書第 II 部針對財務面分析計算投資報酬率的重要性及定量分析預測利益時所應考量的變數,還舉出診斷與治療間關係之測量與分析的實例,證明與診斷好處相關的 3 個假說等。共計 10 頁的內容綱要摘記如下:

序章

計算投資報酬率的理由

利益預測

根據實例計算投資報酬率的論證方法

  • Diaceutics 模式
  • 變數

根據實例論證的情境分析

  • 假說 1:診斷困難時,會加快新藥投入到臨床領域中的使用
  • 假說 2:監視觀察能提昇患者長期服用藥物的有效性
  • 假說 3:有效管理的診斷計畫,能消除患者人口中的限制使保險費用正當化

診斷合作關係之評價

目錄

Abstract

In This Issue...

As the promise of diagnostic/therapeutic combinations is increasingly recognized, pharmaceutical companies must determine best practices in terms of comarketing these combinations. This two-part series is designed to showcase fundamental considerations in diagnostic/drug comarketing plans. Part 1 of this series examined the potential benefit that drug companies can gain from entering into well-planned marketing collaborations with diagnostics companies and presented a framework on which to build these collaborations. In Part 2, we focus on the importance of the financial justification for those collaborations. To highlight the importance of this analysis, we discuss the variables that must be considered when quantifying the expected return. We review three hypotheses often encountered when determining the benefit of a diagnostic, applying to them historical cases in which the relationships between diagnosis and treatment can be measured or analyzed and used as benchmarks when estimating the financial return on new ventures.

Table of Contents

Introduction

Reasons for Calculating the Return on Investment

Estimates of Return

Using Case-Based Reasoning to Calculate the Return on Investment

  • The Diaceutics Model
  • Variables

Analyzing Scenarios Using Case-Based Reasoning

  • Hypothesis 1: A Related Diagnostic Will Accelerate the Uptake of a Novel Drug in Clinical Areas Where Diagnosis Is Difficult
  • Hypothesis 2. A Related Monitoring Test Will Improve Patient Compliance with a Drug That Requires Long-Term Use
  • Hypothesis 3. A Well-Managed Diagnostic Program Can Justify Premium Pricing, Offsetting Restrictions in the Size of the Patient Pool

Evaluating a Diagnostic Partnership

Back to Top